The FDA has agreed to review an application from Roche that seeks approval in the U.S. of obinutuzumab as a treatment for ...

Lupus is an autoimmune disease where the body’s immune system attacks its own tissues and organs, causing inflammation and ...

Learning the facts about lupus can mean the difference between early treatment and serious complications that impact quality ...

Adding anifrolumab to standard treatment for systemic lupus erythematosus led to faster achievement of low disease activity ...

Carla Day was diagnosed with lupus in January 1988. After struggling and persevering with the disease for over 30 years, she ...

Lupus symptoms include inflammation, skin rashes, joint pain and organ damage. To date, treatments have focused on immunosuppressive drugs, which slow down the progression of the disease but often ...

Twice-daily deucravacitinib 3 mg and 6 mg significantly improved cutaneous lupus erythematosus activity by week 16, according ...

The Lupus Research Alliance (LRA) is proud to announce the inaugural recipients of the new Targeted Research Program on ...

The cause of rashes can vary, spanning allergic reactions, infections, autoimmune diseases and environmental irritants.

Living with lupus can be overwhelming, says columnist Candace Semien, but it's important to hold tight and fight for yourself ...

New research reveals disturbing nightmares and hallucinations may serve as early warning signs of lupus, potentially helping patients receive treatment sooner.

The Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for obinutuzumab (Gazyva®) for the treatment of lupus nephritis.